Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Documenti analoghi

• Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
  di: Wang, Michael, et al.
  Pubblicazione: (2013)
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  di: Dimopoulos, M A, et al.
  Pubblicazione: (2017)
• A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
  di: Alsina, Melissa, et al.
  Pubblicazione: (2020)
• A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
  di: O’Connor, Owen A., et al.
  Pubblicazione: (2009)
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
  di: Siegel, David S., et al.
  Pubblicazione: (2012)